Press Release
Nov 04 2025
FORE Biotherapeutics to Participate in Upcoming Investor Conferences
Read more
Press Release
Apr 01 2026
FORE Biotherapeutics Receives Breakthrough Therapy Designation for Plixorafenib
Read more
Press Release
Sep 24 2025
FORE Biotherapeutics Announces Positive Outcome From a Planned Interim Efficacy Analysis for the FORTE Basket Study Evaluating Plixorafenib as a Monotherapy for Recurrent or Progressive BRAF V600 Primary CNS Tumors
Read more
Press Release
Sep 12 2025
FORE Biotherapeutics Presents Phase 1/2a Plixorafenib Data Demonstrating Prolonged Duration of Effect in BRAF Altered Thyroid Cancers at American Thyroid Association® 2025 Annual Meeting
Read more
Press Release
Aug 27 2025
FORE Biotherapeutics to Participate in Upcoming Investor Conferences
Read more
Press Release
May 27 2025
FORE Biotherapeutics to Participate in the Jefferies Global Healthcare Conference
Read more
Press Release
May 22 2025
FORE Biotherapeutics Raises $38 Million in Series D-2 Financing for the Continued Advancement of Plixorafenib
Read more
Press Release
Apr 30 2025
FORE Biotherapeutics to Present Plixorafenib Abstract at the 2025 American Society of Clinical Oncology Annual Meeting
Read more
Press Release
Apr 25 2025
FORE Biotherapeutics Presents New Plixorafenib Results at AACR 2025 Demonstrating Pharmacodynamic Effect in Clinical Tumor Biopsies and Decreased V600E Mutant Allele Frequency in ctDNA of 85% of Patients
Read more
Press Release
Mar 31 2025
FORE Biotherapeutics to Present Two Plixorafenib Abstracts at the American Association for Cancer Research Annual Meeting 2025
Read more